Jupiter Life Line Hospitals (JLHL) Q1 24/25 earnings summary

Executive summary

• Q1 FY2025 saw strong revenue growth driven by increased patient volumes and occupancy, with all three hospitals receiving Gold Tier NABH digital accreditation and the launch of da Vinci robotic surgeries.

• Expansion included 22 new beds in Pune and ongoing construction for 75 additional beds in Indore, with Dombivli hospital construction and regulatory approvals for a new Pune hospital progressing.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved by the Board on August 9, 2024.

• Appointment of M/s. Varma & Varma as Internal Auditor for FY 2024-25 and Mr. Amar Manjrekar as Non-Executive Independent Director for five years.

Financial highlights

• Total income for Q1 FY2025 was INR 288.6 crore, up 18.2% year-over-year, with EBITDA reaching INR 65.3 crore and a margin of 22.6%.

• PAT was INR 44.6 crore, down 17% year-over-year due to a one-time deferred tax benefit in Q1 FY2024.

• Standalone revenue from operations for Q1 FY25 was ₹2,394.06 million, with standalone net profit at ₹406.50 million.

• Consolidated revenue from operations for Q1 FY25 was ₹2,871.25 million, with consolidated net profit at ₹446.05 million.

• Basic EPS for Q1FY25 was ₹6.80.

Outlook and guidance

• Growth in the next 1-2 years will be driven by increased occupancy and capacity in Pune and Indore, with further expansion planned in Dombivli and a new Pune hospital.

• Management expects margins to reach around 25% as hospitals mature over the next three years.

• No immediate plans for self-payer price hikes; potential adjustments may occur at year-end or next year.

• Continued focus on expanding capacity and leveraging technology for improved patient care.